8-K: Travere Therapeutics Plans sNDA Submission for FILSPARI in FSGS Following Positive FDA Meeting

Travere Therapeutics announces plans to submit a supplemental New Drug Application (sNDA) to the FDA for FILSPARI to treat focal segmental glomerulosclerosis (FSGS) based on existing clinical data.

Summary

• Travere Therapeutics has completed a Type C meeting with the FDA regarding FILSPARI for focal segmental glomerulosclerosis (FSGS).
• The company plans to submit a supplemental New Drug Application (sNDA) for traditional approval of FILSPARI for FSGS around the end of the first quarter of 2025.
• The sNDA will be based on data from the Phase 3 DUPLEX and Phase 2 DUET studies.
• The submission follows a public workshop led by the PARASOL workgroup, which found that proteinuria reduction over 24 months is strongly associated with reduced kidney failure risk in FSGS patients.
• If approved, FILSPARI could be the first and only approved medicine for FSGS, a rare kidney disorder and a leading cause of kidney failure.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress with the FDA and the planned sNDA submission, but tempered by the inherent risks and uncertainties associated with regulatory approvals and commercialization.

Positives

• The planned sNDA submission for FILSPARI represents a significant step towards providing a potential treatment option for FSGS patients.
• The PARASOL workgroup findings provide strong support for the clinical relevance of proteinuria reduction as an endpoint in FSGS trials.
• FILSPARI has the potential to be the first and only approved medicine indicated for FSGS.

Risks

• There is no guarantee that the FDA will accept the sNDA for filing or grant approval of FILSPARI for FSGS.
• The company faces risks related to its business and finances in general, the success of its commercial products, and the development of its pipeline.
• Risks are associated with the regulatory review and approval process, enrollment of clinical trials for rare diseases, and the success of ongoing or planned clinical trials.
• The company faces risks associated with the ongoing commercial launch of FILSPARI in IgAN, the timing and potential outcome of its and its partners clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the new administration and matters related to the funding and staffing of government agencies including the FDA.
• The company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the company's products, and technological changes that may limit demand for the company's products.
• The company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company plans to submit an sNDA for FILSPARI in FSGS around the end of the first quarter of 2025 and anticipates potential approval, making it the first and only approved medicine for FSGS.

Industry Context

The announcement is relevant to the rare kidney disease treatment landscape, particularly concerning FSGS. The PARASOL workgroup's findings highlight the importance of proteinuria reduction as a clinical endpoint, potentially influencing future drug development and regulatory decisions in this area.

Stakeholder Impact

• Positive impact on FSGS patients and their families if FILSPARI is approved.
• Potential positive impact on shareholders due to the potential for increased revenue and market share.
• Potential impact on employees through continued employment and growth opportunities.

Next Steps

• Submission of the sNDA to the FDA for FILSPARI in FSGS.
• FDA review of the sNDA.
• Potential commercial launch of FILSPARI for FSGS, pending FDA approval.

Key Dates

Keywords

FILSPARI, FSGS, sNDA, FDA, Travere Therapeutics, DUPLEX, DUET, PARASOL, Proteinuria, Kidney Failure